Landmark Troponin Assay to Give Results at the Point-of-Care
27 Nov 2013
Find out more about the new Meritas® Troponin I point-of-care test, showcased by Trinity Biotech at Medica this year. Enabling fast, accurate triage and intervention of patients at the emergency department, this assay has the potential to generate significant cost savings, reduce turnaround times, and have a massive impact on patient care. Filmed by SelectScience at MEDICA 2013.
About the company
Trinity Biotech Plc
Trinity Biotech plc is a public company, specialising in the development, manufacture and marketing of clinical diagnostic products.
Our Vision
Trinity Biotech will establish positions of leadership in its chosen diagnostics segments through a combination of R&D, acquisitions and strategic investments.
Related products
Request Quote for All Products
Meritas® cTnI Test
Trinity Biotech PlcThe Meritas® cTnI test is a single use, rapid one-step fluorescence immunoassay for in vitro quantitative determination of cTnI in EDTA anticoagulated human whole blood and plasma specimens. Meritas® cTnI test can both be used as an aid in the diagnosis of MI but also for risk stratification of patients with MI in respect to their relative risk of mortality. The test is to be used with the Trinity Biotech Meritas® POC Analyzer. GUIDELINE COMPLIANT PERFORMANCE First and only true POC test able to provide results consistent with the Third Universal Definition of Myocardial Infarction < 10% CV at the 99th percentile Upper Reference Limit (URL) Enables compliance to the NACB Troponin recommended turnaround time of 30 minutes Top laboratory quality at the POC CONFIDENCE, SPEED AND EFFICIENCY: No lengthy wait for lab results Triage patients quicker than before Send healthy patients home without needless delay Admit patients to get proper treatment earlier Maximize the use of resources and hospital beds on only those in need of care Reduce ED overcrowding
Meritas® POC Analyzer
Trinity Biotech PlcThe Meritas® cTnI test is a single use, rapid one-step fluorescence immunoassay for in vitro quantitative determination of cTnI in EDTA anticoagulated human whole blood and plasma specimens. Meritas® cTnI test can both be used as an aid in the diagnosis of MI but also for risk stratification of patients with MI in respect to their relative risk of mortality. The test is to be used with the Trinity Biotech Meritas® POC Analyzer. GUIDELINE COMPLIANT PERFORMANCE First and only true POC test able to provide results consistent with the Third Universal Definition of Myocardial Infarction < 10% CV at the 99th percentile Upper Reference Limit (URL) Enables compliance to the NACB Troponin recommended turnaround time of 30 minutes Top laboratory quality at the POC CONFIDENCE, SPEED AND EFFICIENCY: No lengthy wait for lab results Triage patients quicker than before Send healthy patients home without needless delay Admit patients to get proper treatment earlier Maximize the use of resources and hospital beds on only those in need of care Reduce ED overcrowding